Clinical Trials
8 trialsNCT07022483 2026-05-28
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting
NCT07126561 2026-01-08
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
University of Chicago
Phase 2 Not yet recruiting
NCT02564900 2024-01-22
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT03383692 2023-12-11
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT03368196 2022-11-03
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
Daiichi Sankyo
Phase 1 Completed
NCT03366428 2022-04-12
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
Daiichi Sankyo
Phase 1 Completed
NCT03384940 2021-10-18
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
Daiichi Sankyo
Phase 2 Completed